Could a single chemo drug replace the standard doublet for some ovarian cancers?

This study compares a single chemotherapy drug (paclitaxel) to the standard two-drug combo (paclitaxel plus carboplatin) as initial treatment before surgery for advanced ovarian cancer. It is for patients whose tumors have high levels of a protein called PARK2, which may make them more sensitive to paclitaxel. The goal is to see if the single drug works just as well but causes fewer side effects and delays resistance to platinum drugs. About 60 women will take part.